SDF Application in Oral Cancer Patients to Prevent Dental Caries
Primary Purpose
Dental Caries
Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
silver diamine fluoride, 38%
Sodium fluoride gel, 5000 PPM
Sponsored by
About this trial
This is an interventional treatment trial for Dental Caries focused on measuring Oral and Pharyngeal Cancer, Xerostomia, Silver diamine fluoride, Sodium fluoride gel 5000 PPM
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Head and Neck cancer
Exclusion Criteria:
- Prognosis less than 1 year
- Radiation field of treatment does not involve jaws
Sites / Locations
- Baylor College of Dentistry
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Package
Gel Alone
Arm Description
Topical application of 38% silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
Placebo application of silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
Outcomes
Primary Outcome Measures
Dental Caries (DMFS)
Dental Caries Surfaces determined by intraoral inspection
Secondary Outcome Measures
Gingival Index
Silness and Loe Gingival Index for assessment of gingival condition (0 to 3) determined clinically
Bleeding Index
Bleeding at 6 sites of each tooth determined clinically
Oral Health Quality of Life
Questionnaire
MD Anderson Symptom Inventory-Head and Neck
Questionnaire
Full Information
NCT ID
NCT05403125
First Posted
May 30, 2022
Last Updated
May 30, 2022
Sponsor
Texas A & M University Baylor College Of Dentistry
Collaborators
University of Washington
1. Study Identification
Unique Protocol Identification Number
NCT05403125
Brief Title
SDF Application in Oral Cancer Patients to Prevent Dental Caries
Official Title
Silver Diamine Fluoride: Novel Addition to the Prophylactic Bundle for Dental Management of Radiation-Induced Dental Caries in Oral and Pharyngeal Cancer Patients
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 1, 2022 (Anticipated)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Texas A & M University Baylor College Of Dentistry
Collaborators
University of Washington
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The Texas A & M College of Dentistry, with partner Texas Oncology-Baylor Charles A. Sammons Cancer-Center Radiation-Oncology, proposes to conduct a preliminary clinical study (NIH Stage 0) to pilot test a randomized clinical trial of the efficacy of professionally applied 38% silver diamine fluoride to prevent tooth decay in 60 patients who are being treated with radiation for life threatening head and neck cancer.
Detailed Description
Head and neck cancer has increased in Texas over the last two decades. Radiation-induced tooth decay is a devastating yet potentially preventable side effect of the cancer treatment. Silver diamine fluoride, already the standard of care in children, is inexpensive, easy to apply, and safe. The objective of the research is to conduct a single site pilot RCT (NIH Stage 0) to determine feasibility and preliminarily assess the efficacy of 38% silver diamine fluoride and 5000 PPM fluoride gel for prevention of radiation-induced dental caries over 6 months. Eligible participants will be up to 60 head and neck cancer patients who are scheduled for radiotherapy. The proposed intervention will be applied within 1 m before and at 1- and 3-m post radiation. The primary outcome is dental caries surfaces at 6 months post-radiotherapy (DMFS).Secondary outcomes are The Gingival Index, Gingival Bleeding Index, MDASI-HN, and Oral Health Quality of Life score will be secondary outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dental Caries
Keywords
Oral and Pharyngeal Cancer, Xerostomia, Silver diamine fluoride, Sodium fluoride gel 5000 PPM
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Trial, Intention to Treat
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Test and placebo drugs will be identical in appearance and labeled by the manufacturer as A and B. The biostatistician will generate an assignment list. Individual packets will be prepared, and the clinician will open the packet to determine which study drug to apply. The packets and the drug containers will be color coded to minimize error. In each case a second staff member will verify on site that the participant received the correct coded treatment. Blinding: Participants and the examiners will be blind to treatment.
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Package
Arm Type
Experimental
Arm Description
Topical application of 38% silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
Arm Title
Gel Alone
Arm Type
Active Comparator
Arm Description
Placebo application of silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
Intervention Type
Device
Intervention Name(s)
silver diamine fluoride, 38%
Other Intervention Name(s)
Advantage Silver Dental Arrest
Intervention Description
Topical application to all surfaces of the teeth
Intervention Type
Device
Intervention Name(s)
Sodium fluoride gel, 5000 PPM
Other Intervention Name(s)
Elevate FluoriMax 5000R
Intervention Description
Gel applied after application of silver diamine fluoride and dispensed for home use
Primary Outcome Measure Information:
Title
Dental Caries (DMFS)
Description
Dental Caries Surfaces determined by intraoral inspection
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Gingival Index
Description
Silness and Loe Gingival Index for assessment of gingival condition (0 to 3) determined clinically
Time Frame
6 months
Title
Bleeding Index
Description
Bleeding at 6 sites of each tooth determined clinically
Time Frame
6 months
Title
Oral Health Quality of Life
Description
Questionnaire
Time Frame
6 months
Title
MD Anderson Symptom Inventory-Head and Neck
Description
Questionnaire
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of Head and Neck cancer
Exclusion Criteria:
Prognosis less than 1 year
Radiation field of treatment does not involve jaws
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amal Noureldin, DDS
Phone
214-828-8354
Email
anoureldin@tamu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amal Noureldin, DDS
Organizational Affiliation
TAMU Baylor College of Dentistry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baylor College of Dentistry
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amal Noureldin, DDS
Phone
214-828-8354
Email
anoureldin@tamu.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
SDF Application in Oral Cancer Patients to Prevent Dental Caries
We'll reach out to this number within 24 hrs